Barclays PLC Reduces Stake in Zimmer Biomet Holdings

Medical device maker Zimmer Biomet sees institutional investor decrease ownership

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Barclays PLC, a major institutional investor, decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.6% in the third quarter, according to a recent SEC filing. Barclays now owns approximately 489,056 shares of the medical equipment provider's stock, valued at around $48.2 million.

Why it matters

Zimmer Biomet is a leading global medical device company focused on musculoskeletal healthcare products. Changes in institutional ownership can signal shifts in investor sentiment and market expectations for the company's performance.

The details

According to the SEC filing, Barclays sold 34,741 shares of Zimmer Biomet during the third quarter, reducing its total stake to about 0.25% of the company's outstanding shares. Several other institutional investors and hedge funds have also recently adjusted their positions in ZBH, with some increasing and others decreasing their holdings.

  • Barclays decreased its Zimmer Biomet holdings in the third quarter of 2026.

The players

Barclays PLC

A major global financial services provider and institutional investor.

Zimmer Biomet Holdings, Inc.

A global medical device company focused on musculoskeletal healthcare products.

Got photos? Submit your photos here. ›

The takeaway

The decrease in Barclays' Zimmer Biomet holdings could signal a shift in investor sentiment towards the medical device company, though broader market and industry trends will likely continue to shape the stock's performance.